Compare MXL & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MXL | NNNN |
|---|---|---|
| Founded | 2003 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.5B |
| IPO Year | 2010 | 2025 |
| Metric | MXL | NNNN |
|---|---|---|
| Price | $19.19 | $34.77 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $20.25 | N/A |
| AVG Volume (30 Days) | ★ 972.8K | 37.0K |
| Earning Date | 01-29-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | ★ $423,372,000.00 | $6,920,153.00 |
| Revenue This Year | $30.54 | N/A |
| Revenue Next Year | $18.23 | N/A |
| P/E Ratio | ★ N/A | $668.91 |
| Revenue Growth | ★ 7.53 | N/A |
| 52 Week Low | $8.35 | $5.18 |
| 52 Week High | $25.73 | $55.65 |
| Indicator | MXL | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 59.03 | N/A |
| Support Level | $17.90 | N/A |
| Resistance Level | $19.12 | N/A |
| Average True Range (ATR) | 0.77 | 0.00 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 75.06 | 0.00 |
MaxLinear Inc is a provider of radio frequency and mixed-signal integrated circuits for cable and satellite broadband communications, the connected home, and for data center, metro, and long-haul fiber networks. The company's radio frequency receiver products capture and process digital and analog broadband signals to be decoded for various applications. Its product options include both radio frequency receivers and radio frequency receiver systems-on-chips. The company's products enable the distribution and display of broadband video and data content in a wide range of electronic devices.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.